Literature DB >> 17141593

The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results.

G Zaninotto1, F Minnei, E Guirroli, M Ceolin, G Battaglia, A Bellumat, G Betetto, L Bozzola, M Cassaro, G Cataudella, N Dal Bò, F Farinati, G Florea, A Furlanetto, E Galliani, B Germanà, A Guerini, E Macrì, V Marcon, G Mastropaolo, A Meggio, G Miori, L Morelli, B Murer, L Norberto, R Togni, F Valiante, M Rugge.   

Abstract

BACKGROUND: The natural history of Barrett's Oeosphagus is not completely clarified and Barrett's Oeosphagus Registries are considered useful tools to expand our knowledge on this disease. A Barrett's Oeosphagus Registry has been therefore established in the Veneto Region and neighbouring provinces. AIMS: The aims of the Registry are to assess the demographical, endoscopical and histological characteristics of Barrett's Oeosphagus patients; the prevalence of non-invasive neoplasia and Barrett's Adenocarcinoma and the timing and incidence of Barrett's Oeosphagus progression to malignancy.
METHODS: An interdisciplinary committee of endoscopists, pathologists and information technology experts was established in 2004 to design a website-based Barrett's Oesophagus Registry for the Veneto Region and neighbouring north-eastern Italian provinces. Protocols for endoscopies and biopsies and standard reports were carefully defined.
RESULTS: In the first 18 months, 397 patients with endoscopically visible and histologically proven Barrett's Oeosphagus were enrolled in the Registry; the median age of these patients was 66 years (male:female=3:1). Most patients (75%) had a Short Segment of Barrett's Oesophagus (<or=3 cm) and only 1 in 4 had a Long Segment of Barrett's Oesophagus (>3 cm). Long Segment of Barrett's Oesophagus patients were 5 years older than the Short Segment of Barrett's Oesophagus patients (p<0.05), suggesting a progression from Short Segment of Barrett's Oesophagus to Long Segment of Barrett's Oesophagus. Though no data are available on the incidence of non-invasive neoplasia or Barrett's Adenocarcinoma (i.e., progression to cancer at least 12 months after enrolment), the prevalence of neoplastic lesions (found within 12 months of enrolment) was 5% for Short Segment of Barrett's Oesophagus and 19% for Long Segment of Barrett's Oesophagus, indicating that a careful multiple-biopsy endoscopic protocol is needed, especially when Long Segment of Barrett's Oesophagus are suspected at endoscopy. The prevalence of Barrett's Adenocarcinoma among patients with non-invasive neoplasia was 1/17 cases of low-grade non-invasive neoplasia and 2/3 cases of high-grade non-invasive neoplasia, indicating that these patients require strict endoscopic and bioptic follow-up.
CONCLUSION: A regional Barrett's Oeosphagus Registry is feasible at a relatively low cost and enables significant data to be collected in a relatively short time. The use of a standardised endoscopic nomenclature and report form, a strict biopsy protocol, a standard report for pathologists improves the quality of endoscopic and histological diagnoses.

Entities:  

Mesh:

Year:  2006        PMID: 17141593     DOI: 10.1016/j.dld.2006.09.021

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  11 in total

Review 1.  Long Noncoding RNAs in the Pathogenesis of Barrett's Esophagus and Esophageal Carcinoma.

Authors:  John M Abraham; Stephen J Meltzer
Journal:  Gastroenterology       Date:  2017-05-18       Impact factor: 22.682

Review 2.  Natural history of Barrett's esophagus.

Authors:  Rao Milind; Stephen E Attwood
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

Review 3.  miRNAs in precancerous lesions of the gastrointestinal tract.

Authors:  Matteo Fassan; Carlo M Croce; Massimo Rugge
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

4.  MicroRNA expression profiling in human Barrett's carcinogenesis.

Authors:  Matteo Fassan; Stefano Volinia; Jeff Palatini; Marco Pizzi; Raffaele Baffa; Marina De Bernard; Giorgio Battaglia; Paola Parente; Carlo M Croce; Giovanni Zaninotto; Ermanno Ancona; Massimo Rugge
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

5.  Photodynamic Therapy for Barrett's Esophagus and Esophageal Carcinoma.

Authors:  Bashar J Qumseya; Waseem David; Herbert C Wolfsen
Journal:  Clin Endosc       Date:  2013-01-31

6.  Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis.

Authors:  Matteo Fassan; Marco Pizzi; Giorgio Battaglia; Luciano Giacomelli; Paola Parente; Paolo Bocus; Ermanno Ancona; Massimo Rugge
Journal:  J Clin Pathol       Date:  2010-08       Impact factor: 3.411

Review 7.  BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia.

Authors:  Cathy Bennett; Paul Moayyedi; Douglas A Corley; John DeCaestecker; Yngve Falck-Ytter; Gary Falk; Nimish Vakil; Scott Sanders; Michael Vieth; John Inadomi; David Aldulaimi; Khek-Yu Ho; Robert Odze; Stephen J Meltzer; Eamonn Quigley; Stuart Gittens; Peter Watson; Giovanni Zaninotto; Prasad G Iyer; Leo Alexandre; Yeng Ang; James Callaghan; Rebecca Harrison; Rajvinder Singh; Pradeep Bhandari; Raf Bisschops; Bita Geramizadeh; Philip Kaye; Sheila Krishnadath; M Brian Fennerty; Hendrik Manner; Katie S Nason; Oliver Pech; Vani Konda; Krish Ragunath; Imdadur Rahman; Yvonne Romero; Richard Sampliner; Peter D Siersema; Jan Tack; Tony C K Tham; Nigel Trudgill; David S Weinberg; Jean Wang; Kenneth Wang; Jennie Y Y Wong; Stephen Attwood; Peter Malfertheiner; David MacDonald; Hugh Barr; Mark K Ferguson; Janusz Jankowski
Journal:  Am J Gastroenterol       Date:  2015-04-14       Impact factor: 10.864

Review 8.  Prevention Strategies for Esophageal Cancer-An Expert Review.

Authors:  Elisa Marabotto; Gaia Pellegatta; Afscin Djahandideh Sheijani; Sebastiano Ziola; Patrizia Zentilin; Maria Giulia De Marzo; Edoardo Giovanni Giannini; Matteo Ghisa; Brigida Barberio; Marco Scarpa; Imerio Angriman; Matteo Fassan; Vincenzo Savarino; Edoardo Savarino
Journal:  Cancers (Basel)       Date:  2021-05-01       Impact factor: 6.639

9.  Predictable Marker for Regression of Barrett's Esophagus by Proton Pump Inhibitor Treatment in Korea.

Authors:  Hyun Jin Jo; Hye Seung Lee; Nayoung Kim; Ryoung Hee Nam; Hyun Chang; Min Soo Kim; Sung Eun Kim; Jane C Oh; Dong Ho Lee; Hyun Chae Jung
Journal:  J Neurogastroenterol Motil       Date:  2013-04-16       Impact factor: 4.924

10.  MicroRNA Expression Profiling in the Histological Subtypes of Barrett's Metaplasia.

Authors:  Matteo Fassan; Stefano Volinia; Jeff Palatini; Marco Pizzi; Cecilia Fernandez-Cymering; Mariangela Balistreri; Stefano Realdon; Giorgio Battaglia; Rhonda Souza; Robert D Odze; Giovanni Zaninotto; Carlo M Croce; Massimo Rugge Md Facg
Journal:  Clin Transl Gastroenterol       Date:  2013-05-16       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.